The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)
Collaboration Deals
Joint Ventures
Staged Exits
Milestone Agreements
Indemnification vs. Warranties
Sub-licensing structures
Big pharma deal terms
Speakers:
Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus
Related Insights
August 8, 2025
Foley Ignite
The Rise of "Acquihiring" in a Post-Layoff Tech Sector
As a practicing M&A attorney representing both strategic acquirers and venture-backed targets, I have had a front row seat to the…
August 7, 2025
Manufacturing Industry Advisor
Tariffs and Your Contracts: Why do pricing and tax provisions matter?
President Trump’s shakeup of U.S. trade policy with its approach to tariffs is costing companies billions of dollars.
August 7, 2025
Foley Viewpoints
USPTO Addresses Reports of New Patent Fee Structure
In a recent webinar hosted by the Licensing Executives Society, U.S. Patent and Trademark Office acting Director Coke Morgan Stewart…